Online inquiry

IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11277MR)

This product GTTS-WQ11277MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets hly gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033
UniProt ID P09616
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11277MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14750MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ11912MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ12732MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ13951MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ14090MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ11676MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ11561MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ832MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW